For melanoma, the patients with low HSP90AB1 and MME expression in metastatic tumor samples and the patients with low RPS6KB1 expression in primary tumor samples were correlated with significantly longer survival than the corresponding high expression cohorts (Fig 5B–5D). Here, RPS6KB1 is linked to neoplasm.